Literature DB >> 25176398

Regional therapy in metastatic melanoma: an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion.

Omar M Rashid1, Sarah Sloot, Jonathan S Zager.   

Abstract

INTRODUCTION: The management of locoregioanlly metastatic melanoma of the limb and metastatic melanoma to the liver poses a clinical challenge with limited therapeutic options. An effective therapeutic modality includes regional intraarterial perfusion-based therapy. Percutaneous vascular isolation as in isolated limb infusion (ILI) and percutaneous hepatic perfusion (PHP) provide the additional advantage of minimally invasive techniques to further limit morbidity. AREAS COVERED: This review includes the technical aspects of ILI, PHP, the chemotherapeutic agents used and clinical responses. Also reviewed are pharmacokinetics and novel methods to enhance delivery of chemotherapeutics for both ILI and PHP and the efforts to improve therapeutic response and limit toxicity. EXPERT OPINION: Metastatic melanoma, particularly unresectable disease in the liver and in-transit disease in the limb, poses a clinical challenge with few effective treatments available. Although systemic therapy with immunotherapy or targeted therapy is an option, these modalities are associated with some systemic toxicity. Modalities that target treatment regionally, particularly minimally invasive techniques such as ILI and PHP, provide promising options to focus therapy on treating the affected limb or liver. The effectiveness of these minimally invasive methods has been supported by retrospective studies as well as prospective trials.

Entities:  

Keywords:  in-transit melanoma; isolated limb infusion; melanoma liver metastasis; melphalan; percutaneous hepatic perfusion; uveal melanoma

Mesh:

Substances:

Year:  2014        PMID: 25176398     DOI: 10.1517/17425255.2014.951330

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  11 in total

Review 1.  Regional therapies for locoregionally advanced and unresectable melanoma.

Authors:  Evan S Weitman; Jonathan S Zager
Journal:  Clin Exp Metastasis       Date:  2018-05-08       Impact factor: 5.150

Review 2.  Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption: where are we now, and where we are going.

Authors:  Randy S D'Amico; Deepak Khatri; Noah Reichman; Nitesh V Patel; Tamika Wong; Sherese R Fralin; Mona Li; Jason A Ellis; Rafael Ortiz; David J Langer; John A Boockvar
Journal:  J Neurooncol       Date:  2020-02-19       Impact factor: 4.130

Review 3.  Intraarterial drug delivery for glioblastoma mutiforme: Will the phoenix rise again?

Authors:  Shailendra Joshi; Jason A Ellis; Eugene Ornstein; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2015-06-25       Impact factor: 4.130

4.  A murine model of targeted infusion for intracranial tumors.

Authors:  Minhyung Kim; Tara A Barone; Natalia Fedtsova; Anatoli Gleiberman; Chandler D Wilfong; Julie A Alosi; Robert J Plunkett; Andrei Gudkov; Joseph J Skitzki
Journal:  J Neurooncol       Date:  2015-09-16       Impact factor: 4.130

5.  Hepatic Progression-free and Overall Survival After Regional Therapy to the Liver for Metastatic Melanoma.

Authors:  Andrea M Abbott; Matthew P Doepker; Youngchul Kim; Matthew C Perez; Cassandra Gandle; Kerry L Thomas; Junsung Choi; Ravi Shridhar; Jonathan S Zager
Journal:  Am J Clin Oncol       Date:  2018-08       Impact factor: 2.339

6.  Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases.

Authors:  Marybeth S Hughes; Jonathan Zager; Mark Faries; H Richard Alexander; Richard E Royal; Bradford Wood; Junsung Choi; Kevin McCluskey; Eric Whitman; Sanjiv Agarwala; Gary Siskin; Charles Nutting; Mary Ann Toomey; Carole Webb; Tatiana Beresnev; James F Pingpank
Journal:  Ann Surg Oncol       Date:  2015-11-23       Impact factor: 5.344

7.  Antitumor effect of combination of the inhibitors of two new oncotargets: proton pumps and reverse transcriptase.

Authors:  Luana Lugini; Ilaria Sciamanna; Cristina Federici; Elisabetta Iessi; Enrico Pierluigi Spugnini; Stefano Fais
Journal:  Oncotarget       Date:  2017-01-17

8.  Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma.

Authors:  Josip Skoko; Jan Rožanc; Emilie M Charles; Leonidas G Alexopoulos; Markus Rehm
Journal:  BMC Cell Biol       Date:  2018-12-27       Impact factor: 4.241

9.  Examining the In Vitro Efficacy of the IAP Antagonist Birinapant as a Single Agent or in Combination With Dacarbazine to Induce Melanoma Cell Death.

Authors:  Vesna Vetma; Jan Rožanc; Emilie M Charles; Christian T Hellwig; Leonidas G Alexopoulos; Markus Rehm
Journal:  Oncol Res       Date:  2017-03-23       Impact factor: 5.574

Review 10.  Reassessing the Role of Intra-Arterial Drug Delivery for Glioblastoma Multiforme Treatment.

Authors:  Jason A Ellis; Matei Banu; Shaolie S Hossain; Rajinder Singh-Moon; Sean D Lavine; Jeffrey N Bruce; Shailendra Joshi
Journal:  J Drug Deliv       Date:  2015-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.